Lifesciences@Work : We help scientists build their business

Venture Challenge alumnus Ncardia Announces Collaboration Agreement with BlueRock Therapeutics

Ncardia and BlueRock Therapeutics Announce Collaboration Agreement and Licensing of Process Development Technologies for the Manufacture of iPSC-derived Cardiomyocytes.

LEIDEN, the Netherlands & CAMBRIDGE, Mass.–Ncardia and BlueRock Therapeutics today announced an agreement covering process development technologies for the manufacture of induced pluripotent stem cell (iPSC)-derived cardiomyocytes. Under the terms of the agreement, Bluerock gains access to Ncardia’s large-scale production processes and intellectual property for the production of iPSC-derived cardiomyocytes for therapeutic use.

Read more…